Oxaliplatin

Oxaliplatin

Clinical data
Routes of administration	Intravenous
ATC code	L01XA03 (WHO)
Pharmacokinetic data
Bioavailability	Complete
Elimination half-life	~10 - 25 minutes
Excretion	Renal
Identifiers
IUPAC name ethanedioate;platinum(+2)cation; (2-aminocyclohexyl)amine
CAS Number	63121-00-6
PubChem CID	77994
DrugBank	APRD00186
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C8H14N2O4Pt
Molar mass	395.27 g/mol

WikiDoc Resources for Oxaliplatin
Articles
Most recent articles on Oxaliplatin Most cited articles on Oxaliplatin Review articles on Oxaliplatin Articles on Oxaliplatin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Oxaliplatin Images of Oxaliplatin Photos of Oxaliplatin Podcasts & MP3s on Oxaliplatin Videos on Oxaliplatin
Evidence Based Medicine
Cochrane Collaboration on Oxaliplatin Bandolier on Oxaliplatin TRIP on Oxaliplatin
Clinical Trials
Ongoing Trials on Oxaliplatin at Clinical Trials.gov Trial results on Oxaliplatin Clinical Trials on Oxaliplatin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Oxaliplatin NICE Guidance on Oxaliplatin NHS PRODIGY Guidance FDA on Oxaliplatin CDC on Oxaliplatin
Books
Books on Oxaliplatin
News
Oxaliplatin in the news Be alerted to news on Oxaliplatin News trends on Oxaliplatin
Commentary
Blogs on Oxaliplatin
Definitions
Definitions of Oxaliplatin
Patient Resources / Community
Patient resources on Oxaliplatin Discussion groups on Oxaliplatin Patient Handouts on Oxaliplatin Directions to Hospitals Treating Oxaliplatin Risk calculators and risk factors for Oxaliplatin
Healthcare Provider Resources
Symptoms of Oxaliplatin Causes & Risk Factors for Oxaliplatin Diagnostic studies for Oxaliplatin Treatment of Oxaliplatin
Continuing Medical Education (CME)
CME Programs on Oxaliplatin
International
Oxaliplatin en Espanol Oxaliplatin en Francais
Business
Oxaliplatin in the Marketplace Patents on Oxaliplatin
Experimental / Informatics
List of terms related to Oxaliplatin

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as FOLFOX for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility.

Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.

Mechanism of action and efficacy

The exact mechanism of action of oxaliplatin is not known. In vivo studies showed oxaliplatin has anti-tumor activity against colon carcinoma through its (non-targeted) cytotoxic effects. Median patient survival is approximately 5 months greater compared to the previous standard treatment.

Side-effects

Side-effects of oxaliplatin treatment can potentially include:

• Neuropathy, (both an acute, reversible sensitivity to cold and numbness in the hands and feet and a chronic, possibly irreversible foot/leg, hand/arm numbness, often with deficits in proprioception)
• Fatigue
• Nausea, vomiting, and/or diarrhea
• Neutropenia
• Ototoxicity (hearing loss)

In addition, some patients may experience an allergic reaction to platinum-containing drugs.

Oxaliplatin has less ototoxicity and nephrotoxicity than cisplatin and carboplatin.

History

Oxaliplatin was discovered in 1976 at Nagoya City University in Japan by Professor Yoshinori Kidani, who was granted U.S. Patent 4,169,846 over the drug in 1979. Oxaliplatin was subsequently in-licensed by Debiopharm, a Swiss drug company headquartered in Lausanne and developed as an advanced colorectal cancer treatment. Debio licensed the drug to Sanofi-Aventis in 1994. Eloxatin gained European approval in 1999 and FDA approval in 2004.

Patent information

Eloxatin is covered by patent numbers 5338874 (Expiry Apr 07,2013), 5420319 (Expiry Aug 08,2016), 5716988 (Expiry Aug 07,2015) and 5290961 (Expiry Jan 12, 2013) (see Electronic Orange Book patent info for Eloxatin). Exclusivity code I-441, which expires on Nov 04, 2007, is for use combination with infusional 5-FU/LV for adjuvant treatment stage III colon cancer patients who have undergone complete resection primary tumor-based on improvement in disease free survival with no demonstrated benefit overall survival after 4 years. Exclusivity code NCE, New Chemical Entity, expires on Aug 09, 2007.

Additional sources

• Graham J, Mushin M, Kirkpatrick P (2004). "Oxaliplatin" (PDF). Nat Rev Drug Discov. 3 (1): 11–2. PMID 14756144.CS1 maint: Multiple names: authors list (link)

External links

• Eloxatin - web site of manufacturer.
• Virtual Cancer Centre: Oxaliplatin/Eloxatin
• NCI Drug Information Summary on Oxaliplatin